As a consequence, posttranscriptionally decreasing BACE1 is considered a viable strategy for the treatment of AD (Ohno, 2006; Vassar and Kandalepas, 2011; Yan and Vassar, 2014). Here, BACE1 is linked to Alzheimer disease.